Recently, the European Medicines Agency approved the SGLT inhibitors dapagliflozin and sotagliflozin as adjuvant treatments to insulin for T1DM in adults [85], and insulins were already recommended in T2DM in the previous guidelines. Here, INS is linked to type 1 diabetes mellitus.